Ruxandra Draghia-Akli - Mar 3, 2025 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
Section 16
Signature
/s/Mark J. Casey, Attorney-in-Fact
Stock symbol
NVAX
Transactions as of
Mar 3, 2025
Transactions value $
$944,400
Form type
4
Date filed
3/5/2025, 05:04 PM
Previous filing
Nov 13, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX 2025 Non-statutory Stock Option NQ Award $944K +120K $7.87 120K Mar 3, 2025 Common Stock 120K $7.87 Direct F1
transaction NVAX 2025 Restricted Stock Units RSU Award $0 +80K $0.00 80K Mar 3, 2025 Common Stock 80K $0.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.
F2 One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date.